Education
About Us
Working with TipRanks
Follow Us
Standard BioTools (LAB)
NASDAQ:LAB
Total Valuation
Standard BioTools has a market cap or net worth of $450.99M. The enterprise value is $440.21M.
Market Cap$450.99M
Enterprise Value$440.21M
Share Statistics
Standard BioTools has 378,986,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding378,986,360
Owned by Insiders24.24%
Owned by Institutions0.26%
Financial Efficiency
Standard BioTools’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -31.48%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-31.48%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee214.29K
Profits Per Employee-170.62K
Employee Count814
Asset Turnover0.28
Inventory Turnover2.21
Valuation Ratios
The current PE Ratio of Standard BioTools is -4.45. Standard BioTools’s PEG ratio is 0.10.
PE Ratio-4.45
PS Ratio2.63
PB Ratio1.31
Price to Fair Value1.31
Price to FCF-4.07
Price to Operating Cash Flow-4.31
PEG Ratio0.10
Income Statement
In the last 12 months, Standard BioTools had revenue of 174.43M and earned -138.88M in profits. Earnings per share was -0.52.
Revenue174.43M
Gross Profit84.26M
Operating Income-175.24M
Pretax Income-138.31M
Net Income-138.88M
EBITDA-118.14M
Earnings Per Share (EPS)-0.52
Cash Flow
In the last 12 months, operating cash flow was -143.45M and capital expenditures -8.36M, giving a free cash flow of -151.81M billion.
Operating Cash Flow-143.45M
Free Cash Flow-151.81M
Free Cash Flow per Share-0.40
Dividends & Yields
Standard BioTools pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change-47.52%
50-Day Moving Average1.18
200-Day Moving Average1.70
Relative Strength Index (RSI)59.25
Average Volume (3m)1.40M
Important Dates
Standard BioTools upcoming earnings date is May 6, 2025, TBA Not Confirmed.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 6, 2025
Ex-Dividend Date―
Financial Position
Standard BioTools as a current ratio of 5.70, with Debt / Equity ratio of 6.99%
Current Ratio5.70
Quick Ratio5.09
Debt to Market Cap0.05
Net Debt to EBITDA1.13
Interest Coverage Ratio-52.85
Taxes
In the past 12 months, Standard BioTools has paid 573.00K in taxes.
Income Tax573.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Standard BioTools EV to EBITDA ratio is -4.10, with an EV/FCF ratio of -3.19.
EV to Sales2.78
EV to EBITDA-4.10
EV to Free Cash Flow-3.19
EV to Operating Cash Flow-3.38
Balance Sheet
Standard BioTools has $292.87M in cash and marketable securities with $17.82M in debt, giving a net cash position of -$259.88M billion.
Cash & Marketable Securities$292.87M
Total Debt$17.82M
Net Cash-$259.88M
Net Cash Per Share-$0.69
Tangible Book Value Per Share$0.94
Margins
Gross margin is 48.31%, with operating margin of -100.46%, and net profit margin of -79.62%.
Gross Margin48.31%
Operating Margin-100.46%
Pretax Margin-79.29%
Net Profit Margin-79.62%
EBITDA Margin-67.73%
EBIT Margin-77.39%
Analyst Forecast
The average price target for Standard BioTools is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.50
Price Target Upside96.85% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast64.03%
EPS Growth Forecast41.46%